Epic Sciences Talks Differentiation And Benefits Of Its DefineMBC Cancer Test
Executive Summary
Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.
You may also be interested in...
Sysmex picks neighbouring Asian CTC firm for liquid biopsy collaboration
Japanese hematology diagnostics heavyweight Sysmex is partnering with Clearbridge BioMedics, an emerging Singapore company in the field of circulating tumor cell capture technology, to co-develop a new liquid biopsy system for diagnosing and monitoring cancer patients.
INTERVIEW: Roche backing to help speed Liquid Biopsy's CTC test development
Liquid Biopsy, a Swedish firm developing a test for circulating tumour cells (CTCs) for the diagnosis, prognosis and monitoring of cancer, has highlighted the importance of new partner Roche in developing the test for clinical use.
INTERVIEW: New Angle for CTC capture device Parsortix; approval within a year?
Parsortix, a blood-based diagnostic that captures and counts circulating tumour cells (CTCs) for the diagnosis, prognosis and monitoring of cancer, could be approved in around a year, according to Angle, the company developing the device.